ABO 2203
Alternative Names: ABO-2203; mRNA encoding CD19/CD3 T cell engager - Suzhou Guangxin BiosciencesLatest Information Update: 24 Jul 2025
At a glance
- Originator Suzhou Guangxin Biosciences
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; RNA
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- Preclinical Autoimmune disorders
Most Recent Events
- 26 May 2025 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT07072169)
- 26 May 2025 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (SC) (NCT07072169)
- 31 Dec 2024 Suzhou Guangxin Biosciences plans phase-0 trial for Autoimmune disorders (Treatment-resistant) in China (Parenteral, Injection) in December 2024 (NCT06747156)